Therapy of Mucormycosis
AbstractDespite the recent introduction of mold-active agents (posaconazole and isavuconazole), in addition to amphotericin B products, to our armamentarium against mucormycosis, many uncertainties remain for the management of this uncommon opportunistic infection, as there are no data from prospective randomized clinical trials to guide therapy. In this mini-review, we present the current status of treatment options. In view of the heterogeneity of the disease (different types of affected hosts, sites of infection, and infecting Mucorales), mucormycosis management requires an individualized management plan that takes into account the net state of immunosuppression of the host, including comorbidities, certainty of diagnosis, site of infection, and antifungal pharmacological properties. View Full-Text
Share & Cite This Article
Sipsas, N.V.; Gamaletsou, M.N.; Anastasopoulou, A.; Kontoyiannis, D.P. Therapy of Mucormycosis. J. Fungi 2018, 4, 90.
Sipsas NV, Gamaletsou MN, Anastasopoulou A, Kontoyiannis DP. Therapy of Mucormycosis. Journal of Fungi. 2018; 4(3):90.Chicago/Turabian Style
Sipsas, Nikolaos V.; Gamaletsou, Maria N.; Anastasopoulou, Amalia; Kontoyiannis, Dimitrios P. 2018. "Therapy of Mucormycosis." J. Fungi 4, no. 3: 90.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.